Clinical trial
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With…
NCT00447980 · Neurotech Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00447980 |
|---|---|
| Title | A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa |
| Official title | A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome |
| Lead sponsor | Neurotech Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Retinitis Pigmentosa |
| Intervention type | Drug |
| Interventions | NT-501 |
| Enrollment | 73 |
| Start date | Jan 22, 2007 |
| Primary completion | Apr 19, 2010 |
| Completion | Apr 19, 2010 |
| First posted | Mar 15, 2007 |
| Last update posted | May 1, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: